Product imageResearch use only

CAT. NO. DC68141Featured

AMG514

Research highlights

Spleen-biased mRNA deliverySplenic dendritic-cell and macrophage transfectionImmune-remodeling mRNA researchPreclinical RNA cancer-vaccine studies

Pack size & price

USD

Add the cited formulation componentsSelected AMG514 pack + every supporting component at 100 mg each+US$450 / set

Supporting components

DOPE DC33634 · 100 mg+Cholesterol DCD-041 · 100 mg+DMG-PEG2k DC40169 · 100 mg

Components are supplied separately; this is not a premixed LNP. RNA/cargo, buffer and formulation service are not included.

TotalUS$850

We match the best price and quality on market.

Ships from ShanghaiIce-pack transportPure lipid recommended

Product overview

Description & Application

AMG514 is a novel ionizable lipid designed for formulating spleen-targeting lipid nanoparticles (LNPs) to deliver immune‑remodeling mRNAs (IR‑mRNAs). Its key advantage lies in the formation of a unique “protein corona” enriched with vitronectin, coagulation factors, and specific apolipoproteins (e.g., ApoA‑IV), together with its relatively high apparent pKa (~7.5), which actively redirects LNPs to the spleen instead of the liver. This precise spleen‑targeting property enables efficient transfection of splenic antigen‑presenting cells (APCs). As a vaccine adjuvant, AMG514‑LNPs therefore elicit a more robust activation of adaptive immunity compared to conventional LNPs (e.g., cKK‑E12), generating significantly enhanced antigen‑specific CD8⁺ T‑cell and antibody responses, and inducing durable anti‑tumor immune memory in preclinical models.

CAS No.	Not available
Chemical Name	AMG514
Synonyms	AMG-514, AMG 514
SMILES	CCCCCCCCC(CCCCCC)C(=O)OCCCCCCC(O)CN1CCC2(CC1)CCN(CC(O)CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)C2
Formula	C56H108N2O6
M.Wt	905.49
Purity	>95% by ELSD-HPLC
Storage	Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping condition	Ships from Shanghai. Pure lipid is stable during ice-pack transport.
Publication	Gupta A, Das R, Reed K, et al. Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models. Nature Biotechnology. Published online 13 May 2026.

Literature-reported formulation composition

Component	mol%	Role
AMG514	35	Ionizable lipid
DOPE	16	Helper phospholipid
Cholesterol	46.5	Sterol
DMG-PEG2k	2.5	PEG lipid
Reported total	100	Source values retained

Component molecular weights and calculated amounts

Composition retained from the cited study below. Research planning aid only. Results cover lipid component weights and do not include RNA, buffer, solvent, process loss or an N/P ratio.

Total lipid mass (mg)

Component	Normalized mol%	Amount (µmol)	Weight (mg)
AMG514	35.000	51.5894	46.7137
DOPE	16.000	23.5837	17.5470
Cholesterol	46.500	68.5402	26.5011
DMG-PEG2k	2.500	3.6850	9.2382

Calculated total: 100.0000 mg lipid.

Calculated catalog planning quantities; RNA, solvent and process loss are excluded. DMG-PEG2000 uses 2507. Component mass = total lipid mass × molar parts × molecular weight / sum(parts × molecular weight). This conversion does not infer N/P.

N/P ratioNot reported in the cited article

Total lipid:cargo weight ratio10:1 ionizable lipid:RNA (w/w); this is not an N/P ratio

Buffer & pH133 ng/microliter mRNA in 10 mM citrate, pH 3.0; final PBS after buffer exchange, pH 7-7.5

CargoFirefly luciferase mRNA

Administration routeIntravenous injection

Dose1 microgram FLuc mRNA, single dose

Animal modelMouse; strain not stated for the initial reporter-delivery screen

Formulation processStaggered-herringbone microfluidic mixing at 3:1 aqueous:lipid-phase volume ratio and 1.2 mL/min total flow. LNPs were diluted at least four-fold with PBS and concentrated through 100 kDa filters for three exchange cycles.

Literature-reported performance for the cited formulation

Literature-reportedmRNA encapsulation efficiency97%Post-formulation characterization · Representative cKK-E12 LNP: 56%Supplementary Table 2, internal p. 25 / PDF p. 26

Literature-reportedZ-average diameter102.7 nmPost-formulation characterization · Representative cKK-E12 LNP: 86.0 nmSupplementary Table 2, internal p. 25 / PDF p. 26

Literature-reportedPolydispersity index0.133Post-formulation characterization · Representative cKK-E12 LNP: 0.155Supplementary Table 2, internal p. 25 / PDF p. 26

Literature-reportedApparent LNP pKaapproximately 7.5Post-formulation characterization · Approximately 6.5 is described as characteristic of the cited liver-tropic formulationsMain text p. 11; Supplementary Figure 21b

Literature-reportedSplenic FLuc expressionapproximately four-fold higher6 h after a single 1 microgram IV FLuc-mRNA dose · Versus cKK-E12 LNP; reduced liver signal was also reportedMain text p. 9; Extended Data Figure 4c,d

Additional reported findings

Splenic antigen-presenting-cell transfection

In the Ai14/Cre reporter experiment, the plotted fractions were approximately 67% versus 40% tdTomato-positive dendritic cells and approximately 60% versus 40% tdTomato-positive macrophages for AMG514 versus cKK-E12.

Cre mRNA, IV, n=4-5; the figure caption reports 5 micrograms and 48 h, while Methods report 0.25 mg/kg and 72 h · Extended Data Figure 4e and Methods

Antigen-specific CD8 T-cell response

AMG514-formulated NIK plus OVA generated approximately 15% OVA-tetramer-positive CD8 T cells after boosting, compared with approximately 6% for the cKK-E12 formulation.

C57BL/6J mice; total 3 micrograms RNA; days 0 and 14; n=5; route not stated for this experiment · Main Figure 6f-h and text p. 11

B16-OVA tumor challenge

AMG514 NIK plus OVA produced complete rejection in five of five mice, compared with three of five for cKK-E12 NIK plus OVA and one of five for AMG514 OVA alone. The authors state that the AMG514 advantage over cKK-E12 was not statistically significant.

Preclinical prophylactic vaccine and tumor-challenge study · Main Figure 6i,j and text p. 11

Protein-corona profile

The reported AMG514 corona was enriched in vitronectin, coagulation proteins and selected apolipoproteins. This association does not by itself prove a receptor-mediated targeting mechanism.

The main text refers to plasma, while the Supplementary Figure 21 caption refers to serum · Main text p. 11 and Supplementary Figure 21

Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.

Cited literature for this formulation and performance datasetGupta A, Das R, Reed K, et al. Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models. Nature Biotechnology. Published online 13 May 2026. DOI: 10.1038/s41587-026-03115-2
Structure and analytical identity: Extended Data Figure 4a and Supplementary chemical-characterization section; formulation and preparation: Supplementary Table 1 and Methods; reporter delivery: Extended Data Figure 4; vaccination and tumor-challenge findings: Figure 6; protein corona and apparent pKa: main text and Supplementary Figure 21.

Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

Mass = concentration × volume × molecular weight

MassConcentrationVolumeMolecular weightg/mol

Enter any three values to calculate the fourth.

C₁V₁ = C₂V₂

C₁mMV₁mLC₂mMV₂mL

Enter any three values to calculate the fourth.

Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass	1 mM	5 mM	10 mM
10 mg	11.0437 mL	2.2087 mL	1.1044 mL
25 mg	27.6094 mL	5.5219 mL	2.7609 mL
50 mg	55.2187 mL	11.0437 mL	5.5219 mL
100 mg	110.4374 mL	22.0875 mL	11.0437 mL
250 mg	276.0936 mL	55.2187 mL	27.6094 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?

We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.

Pure lipid or solution — which should I choose?

Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.

How should I measure a small amount of oily or viscous lipid?

Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.

Can you support formulation optimization and scale-up?

Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.

AMG514

Pack size & price

Description & Application

Recommended Products

DMA4-H228

Lipid H5T5

113-AA-C8C14

CureVac Lipid C24(CVL1,VitE-C4DE-Pip- S)

A5-CE-C7-6

Sail lipid 7669

Lipid I97

Lipid GL5

C18 NC-TNP

Lipid TOT-5